Perspective Therapeutics (CATX) Receivables - Accured (2022 - 2025)

Perspective Therapeutics has disclosed Receivables - Accured across 3 years of filings, most recently posting $1.0 million for Q4 2025.

• Receivables - Accured for Q4 2025 came in at $1.0 million, up 16.25% year-over-year; the trailing twelve-month figure through Dec 2025 was $1.0 million (up 16.25% YoY), and the FY2025 annual result was $1.0 million, up 16.25% from the prior year.
• Receivables - Accured came in at $1.0 million for Q4 2025 at Perspective Therapeutics, up from $880000.0 in the prior quarter.
• In the past five years, Receivables - Accured ranged from a high of $1.0 million in Q4 2025 to a low of $109000.0 in Q4 2022.
• The 3-year median for Receivables - Accured is $880000.0 (2024), against an average of $670666.7.
• Peak annual rise in Receivables - Accured reached 16.25% in 2025, while the deepest fall reached 16.25% in 2025.
• Perspective Therapeutics' Receivables - Accured stood at $109000.0 in 2022, then soared by 707.34% to $880000.0 in 2024, then rose by 16.25% to $1.0 million in 2025.
• The last three Receivables - Accured figures came in at $1.0 million (Q4 2025), $880000.0 (Q4 2024), and $109000.0 (Q4 2022), per Business Quant data.